The first question is whether the brand states the active concentration explicitly: 1%, or equivalently 10mg/mL. Not "copper peptide serum" or "high-concentration formula" but a specific number the buyer can evaluate against the research.

Research on GHK-Cu spans a range of model systems, including in vitro skin penetration studies, gene expression panels, and subcutaneous animal research, each using its own concentration or dose format. None of this research directly validates 1% as a specific in-use topical concentration, and no brand can honestly claim otherwise. What a stated concentration does allow is scrutiny: a buyer can weigh a known figure against what the literature actually measured, model system by model system. A product that cannot or will not state a specific concentration forecloses that scrutiny entirely. If a brand avoids the question, that is itself informative.

There is a second layer to this question that is almost never addressed directly: 1% of what, exactly? Copper peptide suppliers sell GHK-Cu in multiple forms, including pure powder and pre-dissolved stock solutions of varying concentrations. A formulator using a stock solution at 1% inclusion in the final formula is not producing a 1% GHK-Cu serum in the same sense as a formulator adding 1% pure Copper Tripeptide-1 powder by weight. The actual active concentration in the former case depends on the concentration of the stock solution, which the finished product label does not disclose.

INCI ingredients are listed in descending order of concentration for ingredients present above 1%. Below 1%, any order is permitted by regulation. This creates a useful diagnostic: if Copper Tripeptide-1 appears near the bottom of a long ingredients list, after the preservative system, after a range of botanical extracts or functional agents, the concentration is likely below 1% and potentially substantially lower.

A product that leads with copper peptide marketing, then lists Copper Tripeptide-1 as the penultimate ingredient, is more likely offering a trace inclusion at a marketing-friendly label position than a research-referenced dose. For more on reading INCI order, see what most copper peptide labels don't tell you.

A standalone GHK-Cu serum has one primary active. The carrier system, the pH, the preservative choice, are all optimised for that compound. In a multi-peptide blend, multiple actives are present and a "1%" figure in the product name does not necessarily clarify how that percentage is allocated. A product named "Multi-Peptide + Copper Peptides 1%" does not disclose whether the 1% refers to Copper Tripeptide-1 specifically or to a broader peptide complex. Without an explicit GHK-Cu concentration, the buyer cannot determine how much of the active is actually present.

Multi-peptide formulations are not inferior products: they pursue a different strategy, targeting multiple pathways simultaneously. But a product that does not disclose the individual concentration of each active cannot be evaluated against single-compound research, and should not be treated as equivalent to a serum that does.

GHK-Cu is water-soluble and stable in aqueous carriers. The solvents used alongside water matter for two reasons: skin compatibility and use context.

Glycol solvents, propylene glycol, propanediol, pentylene glycol, are common in cosmetic formulations. They are broadly considered safe and serve a legitimate function in many products. They also cause sensitivity reactions in a meaningful proportion of users, and are widely avoided in microneedling protocols specifically, because the micro-channels created during needling increase dermal absorption of everything applied immediately after, including potential irritants.

For a compound that is frequently used within scalp and skin protocols where microneedling is also employed, a glycol-free aqueous carrier built on glycerin and sodium hyaluronate is the simpler option for users prioritising microneedling compatibility. It is also the less convenient one to manufacture at scale, which is part of why it remains less common in the market.

UK cosmetic products must be notified on the UK Cosmetic Products Notification Portal (SCPN) before they can be placed on the UK market. Notification requires a complete Product Information File including a safety assessment by a qualified assessor. It is a regulatory minimum, not a quality endorsement, but it is a minimum that imported products sold informally through grey channels often do not meet.

For UK buyers, SCPN registration is a basic due diligence filter. A UK-formulated product from a UK brand, registered on the SCPN, has documented and traceable regulatory standing. A product that does not exist in the SCPN database, or that is being shipped from outside the UK without proper import declaration, does not.

Products meeting all five criteria are relatively uncommon, which is part of the reason the research-literate skincare and hair loss community finds this market difficult to navigate.

Against the five criteria: concentration is stated explicitly at 1%; Copper Tripeptide-1 appears third in the INCI list, after water and glycerin, before sodium hyaluronate and the preservative system; it is a standalone serum with a single primary active; the carrier is glycol-free; and it is UK-formulated and SCPN registered.

For the full research background on what GHK-Cu is and what the literature supports, see the GHK-Cu article in the Research and Notes section.

AmpleLab products are cosmetic formulations registered on the UK Cosmetic Products Notification Portal. They are not medicines and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Research references are provided for informational purposes and do not constitute clinical claims.

AmpleLab.